Navigation Links
Rigel Announces Second Quarter 2013 Financial Results
Date:8/6/2013

rd-looking" statements, including, without limitation, statements related to the further development of certain drug candidates, including to the future plans with respect to fostamatanib and the timing of announcement of those plans and the results of certain studies, and the sufficiency of our funds and the timing of our cash.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Rigel's product candidates and our need for additional capital in the future to sufficiently fund our operations and research, the uncertain timing of completion of and the success of clinical trials and the potential problems that may arise in the clinical development process, and that our corporate collaborations or license agreements may be unsuccessful, market competition, risks associated with and Rigel's dependence on Rigel's corporate partnerships, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the three months ended March 31, 2013. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

 

Contact: Ryan D. Maynard
Phone: 650.624.1284'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Rigel Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, ... scientific poster describing an innovative diagnostic procedure for the ... New Light on Disease (SPEC) conference in Krakow, ... poster entitled, "Development of in vitro Diagnostics for Detection ... discussed during the conference poster session on Tuesday, August ...
(Date:8/19/2014)... Aug. 19, 2014  As power morcellator lawsuits ... Bernstein Liebhard LLP notes that women in need ... a number of options that do not involve ... According to a report published by The Wall ... options include a mini-laparotomy and vaginal hysterectomy. Non-surgical ...
(Date:8/19/2014)... -- Research and Markets has announced the addition ... Business Report" report to their offering. ... Drugs in US$ Million by the following Brands: Humatrope, Norditropin, ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , and Rest of World. ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Global Human Growth Hormone Drugs - Strategic Business Report 2014 2
... Dec. 16 Vivakor, Inc. (OTC Bulletin Board: VIVK) ... out of Walnut Creek, California and its affiliate group, ... Consulting has been retained by Vivakor to assist with ... recently reported acquisition strategy. Specifically, Baker Consulting is exploring ...
... , EVANSTON, Ill., Dec. ... innovative treatments for depression and other CNS disorders based on ... presented at a major medical meeting showed that its lead ... signs of the CNS-related side effects seen with other drugs ...
Cached Medicine Technology:Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... a novel approach to treating cancer - using Botox. ... Science Translational Medicine shows that cancer growth ... nerves that are linked to cancer stem cells. The ... made the treatment cheap, safe and efficient. The researchers ... will soon start testing on humans. , The nervous ...
(Date:8/20/2014)... A common approach to treating kidney failure ... improve survival chances for people who suddenly developed the ... University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive ... kidney failure, may not provide a definitive benefit to ...
(Date:8/20/2014)... 2014 (HealthDay News) -- New research reveals that, long ... the global spread of the infectious disease known as ... in Africa to seals and sea lions, who then ... years ago, according to an international team of researchers. ... rise again worldwide. This study and further research will ...
(Date:8/20/2014)... August 20, 2014 Get the report ... with mergermarket presents ‚ÄúDeal Drivers 2014 Half Year Report ... of M&A activity in both North and South America, ... , About Merrill DataSite     , Merrill DataSite is a ... optimises the due diligence process by providing a highly ...
Breaking Medicine News(10 mins):Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2
... , In an observational cohort study from ... on prevention of mother-to-child HIV transmission among women ... recommendations. , Citation: Tonwe-Gold B, Ekouevi DK, Viho ... Antiretroviral treatment and prevention of peripartum and postnatal ...
... a key gene might not be to blame, researchers say ... is poking holes in a prevailing theory on the origins ... to rein in cell-damaging free radicals actually had fewer ... "This finding may go beyond Alzheimer,s into all aging theory," ...
... in no real danger, survey finds , MONDAY, Aug. 20 ... white peers to take risks that boost their odds for ... August issue of the journal Archives of Dermatology , ... Medicine surveyed 369 high school students (221 white Hispanics and ...
... Compared with Caucasians, African-Americans are exposed to more ... of Medicine study published in this months Public Health ... preventable death and disease in the United States, causing ... $150 billion in direct and indirect costs each year; ...
... study likely applicable to men of other ethnicities, Tulane ... drinks per week) may increase the risk of stroke ... published in the latest issue of Annals of Neurology. ... of Tulane University School of Public Health and Tropical ...
... 2007 - Lissamine green sounds like the latest cleaning ... you would want to get in your eyes. , ... patterns that are key to diagnosing dry eye syndrome ... treating the potentially sight-stealing disease, new research at UT ...
Cached Medicine News:Health News:HIV therapy in pregnancy-data support WHO recommendations 2Health News:Study Puts 1 Alzheimer's Theory in Doubt 2Health News:Study Puts 1 Alzheimer's Theory in Doubt 3Health News:Hispanic Teens Take More Skin Cancer Risks 2Health News:Pitt study finds inequality in tobacco advertising 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: